Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib
- 31 December 2005
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 50 (3) , 393-399
- https://doi.org/10.1016/j.lungcan.2005.07.012
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell CarcinomaClinical Cancer Research, 2004
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursBritish Journal of Dermatology, 2004
- Cetuximab in Advanced Non-Small Cell Lung CancerClinical Cancer Research, 2004
- Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cellsInternational Journal of Cancer, 2003
- Prognostic significance of cytokine modulation in non‐small cell lung cancerInternational Journal of Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Clinical applications of TNF-α in cancerCurrent Opinion in Immunology, 1998
- Secretion of functional hematopoietic growth factors by human carcinoma cell linesInternational Journal of Cancer, 1998
- Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human SkinJournal of Investigative Dermatology, 1990